These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 19627169)

  • 1. Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience.
    Renwick W; Pettengell R; Green M
    BioDrugs; 2009; 23(3):175-86. PubMed ID: 19627169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
    Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
    Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK.
    Liu Z; Doan QV; Malin J; Leonard R
    Appl Health Econ Health Policy; 2009; 7(3):193-205. PubMed ID: 19799473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spotlight on pegfilgrastim in chemotherapy-induced neutropenia.
    Frampton JE; Keating GM
    BioDrugs; 2005; 19(6):405-7. PubMed ID: 16392893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
    Crawford J
    Semin Oncol; 2003 Aug; 30(4 Suppl 13):24-30. PubMed ID: 14508717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits.
    Rader M
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):16-21. PubMed ID: 16736984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
    Aapro MS; Cameron DA; Pettengell R; Bohlius J; Crawford J; Ellis M; Kearney N; Lyman GH; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
    Eur J Cancer; 2006 Oct; 42(15):2433-53. PubMed ID: 16750358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
    Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
    J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
    Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia.
    Biganzoli L; Untch M; Skacel T; Pico JL
    Semin Oncol; 2004 Jun; 31(3 Suppl 8):27-34. PubMed ID: 15181606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
    Lyman G; Lalla A; Barron R; Dubois RW
    Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia.
    Ricotta R; Cerea G; Schiavetto I; Maugeri MR; Pedrazzoli P; Siena S
    Future Oncol; 2006 Dec; 2(6):667-76. PubMed ID: 17155894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices.
    Morrison VA; Wong M; Hershman D; Campos LT; Ding B; Malin J
    J Manag Care Pharm; 2007 May; 13(4):337-48. PubMed ID: 17506600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis.
    Cooper KL; Madan J; Whyte S; Stevenson MD; Akehurst RL
    BMC Cancer; 2011 Sep; 11():404. PubMed ID: 21943360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany].
    Sehouli J; Goertz A; Steinle T; Dubois R; Plesnila-Frank C; Lalla A; von Minckwitz G
    Dtsch Med Wochenschr; 2010 Mar; 135(9):385-9. PubMed ID: 20180162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF).
    Naeim A; Henk HJ; Becker L; Chia V; Badre S; Li X; Deeter R
    BMC Cancer; 2013 Jan; 13():11. PubMed ID: 23298389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of chemotherapy-induced neutropenia with pegfilgrastim: pharmacokinetics and patient outcomes.
    Yang BB; Savin MA; Green M
    Chemotherapy; 2012; 58(5):387-98. PubMed ID: 23296266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colony-stimulating factors for the management of neutropenia in cancer patients.
    Dale DC
    Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.
    Weycker D; Malin J; Barron R; Edelsberg J; Kartashov A; Oster G
    Am J Clin Oncol; 2012 Jun; 35(3):267-74. PubMed ID: 21378538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
    Wang L; Baser O; Kutikova L; Page JH; Barron R
    Support Care Cancer; 2015 Nov; 23(11):3131-40. PubMed ID: 25821144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.